Vibostolimab-pembrolizumab for previously untreated PD-L1-positive metastatic non-small cell lung cancer

Vibostolimab-pembrolizumab is currently in clinical development for previously untreated programmed cell death 1 ligand 1 (PD-L1) positive metastatic non-small cell lung cancer (NSCLC). NSCLC is the most common form of lung cancer. Elevated levels of PD-L1 expression are observed on the cell surface of different types of cancer cells, including NSCLC. It is believed that PD-L1 expression allows cancer cells to avoid the immune response. Metastatic cancer refers to cancer that has spread from the part of the body where it started to other parts of the body. Lung cancer remains the leading cause of cancer deaths, and there is need for more treatment options to prolong survival and preserve quality of life.